Institutional Sign In

Go

PHARMOS

PHARMOS's employees fell 9.82% yoy to 441 in 2019

By Helgi Analytics - June 23, 2021

PHARMOS employed 441 employees in 2019, down 9.82% compared to the previous year. Historically, between 2006 and 2019, ...

PHARMOS's net profit rose 128% yoy to CZK 11.2 mil in 2019

By Helgi Analytics - June 23, 2021

PHARMOS made a net profit of CZK 11.2 mil with revenues of CZK 10,337 mil in 2019, up by 128% and up by 1.62%, respec...

PHARMOS's Net Margin rose 124% yoy to 0.108% in 2019

By Helgi Analytics - June 23, 2021

PHARMOS made a net profit of CZK 11.2 mil with revenues of CZK 10,337 mil in 2019, up by 128% and up by 1.62%, respectively,...

Profit Statement 2017 2018 2019
Sales CZK mil 10,899 10,173 10,337
Gross Profit CZK mil 208 382 400
EBITDA CZK mil 53.9 47.3 57.5
EBIT CZK mil 35.2 27.4 37.9
Financing Cost CZK mil ... 29.6 42.2
Pre-Tax Profit CZK mil 25.4 5.87 15.0
Net Profit CZK mil 20.3 4.89 11.2
Dividends CZK mil 19.0 3.06 0.130
Balance Sheet 2017 2018 2019
Total Assets CZK mil 3,440 3,483 3,460
Non-Current Assets CZK mil 219 373 357
Current Assets CZK mil 3,215 3,105 3,099
Working Capital CZK mil 1,702 1,759 1,745
Shareholders' Equity CZK mil 640 642 653
Liabilities CZK mil 2,800 2,842 2,808
Total Debt CZK mil 1,385 1,509 1,473
Net Debt CZK mil ... 1,290 1,245
Ratios 2017 2018 2019
ROE % 3.17 0.764 1.72
ROCE % 1.05 0.241 0.527
Gross Margin % 1.91 3.75 3.87
EBITDA Margin % 0.494 0.465 0.556
EBIT Margin % 0.323 0.269 0.366
Net Margin % 0.186 0.048 0.108
Net Debt/EBITDA ... 27.3 21.7
Net Debt/Equity % ... 201 191
Cost of Financing % ... 2.04 2.83
Cash Flow 2017 2018 2019
Total Cash From Operations CZK mil 68.2 177 7.52
Total Cash From Investing CZK mil -33.3 -241 3.28
Total Cash From Financing CZK mil -20.1 68.9 -46.1
Net Change In Cash CZK mil 14.8 4.31 14.7
Cash Conversion Cycle days 56.9 62.8 61.2
Cash Earnings CZK mil 38.9 24.8 30.8
Free Cash Flow CZK mil 34.9 -64.6 10.8

Get all company financials in excel:

Download Sample   $19.99

overview Unit 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
income statement                            
Sales CZK mil               10,989 10,702 10,628 11,306 10,899    
Gross Profit CZK mil               209 202 204 250 208    
EBIT CZK mil               15.3 23.1 31.0 72.2 35.2    
Net Profit CZK mil               6.41 5.89 13.6 44.3 20.3    
                               
ROE % ...             1.12 1.02 2.33 7.19 3.17    
EBIT Margin %               0.139 0.215 0.291 0.639 0.323    
Net Margin %               0.058 0.055 0.128 0.392 0.186    
Employees               466 438 437 454 456    
balance sheet                            
Total Assets CZK mil               4,043 3,626 3,459 3,713 3,440    
Non-Current Assets CZK mil               219 208 218 203 219    
Current Assets CZK mil               3,801 3,413 3,236 3,500 3,215    
                               
Shareholders' Equity CZK mil               576 579 594 639 640    
Liabilities CZK mil               3,467 3,047 2,865 3,074 2,800    
Non-Current Liabilities CZK mil               4.96 1.73 5.98 0 0    
Current Liabilities CZK mil               3,462 3,046 2,859 3,074 2,800    
                               
Net Debt/EBITDA ... ... ... ... ... ... ... ... ... ... ... ...    
Net Debt/Equity % ... ... ... ... ... ... ... ... ... ... ... ...    
Cost of Financing % ... ... ... ... ... ... ... ... ... ... ... ...    
cash flow                            
Total Cash From Operations CZK mil               -147 126 125 -25.5 68.2    
Total Cash From Investing CZK mil               -22.7 -10.4 -27.4 -9.11 -33.3    
Total Cash From Financing CZK mil               -1.91 -110 -36.3 28.8 -20.1    
Net Change In Cash CZK mil               -172 5.88 61.0 -5.84 14.8    
income statement Unit 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
income statement                            
Sales CZK mil               10,989 10,702 10,628 11,306 10,899    
Cost of Goods & Services CZK mil               10,780 10,500 10,424 11,057 10,691    
Gross Profit CZK mil               209 202 204 250 208    
Staff Cost CZK mil               132 124 125 143 162    
Other Operating Cost (Income) CZK mil               37.8 32.8 26.8 11.5 -7.33    
EBITDA CZK mil               39.6 45.3 51.8 94.9 53.9    
Depreciation CZK mil               24.3 22.2 20.9 22.7 18.6    
EBIT CZK mil               15.3 23.1 31.0 72.2 35.2    
Net Financing Cost CZK mil               10.2 15.4 6.37 16.9 9.79    
Financing Cost CZK mil ... ... ... ... ... ... ... ... ... ... ... ...    
Financing Income CZK mil ... ... ... ... ... ... ... ... ... ... ... ...    
FX (Gain) Loss CZK mil ... ... ... ... ... ... ... ... ... ... ... ...    
Extraordinary Cost CZK mil               0 0 0 0 0    
Pre-Tax Profit CZK mil               5.12 7.67 24.6 55.4 25.4    
Tax CZK mil               -1.29 1.78 10.9 11.0 5.18    
Minorities CZK mil               0 0 0 0 0    
Net Profit CZK mil               6.41 5.89 13.6 44.3 20.3    
Net Profit Avail. to Common CZK mil               6.41 5.89 13.6 44.3 20.3    
Dividends CZK mil ...             3.46 2.72 -1.23 -0.359 19.0    
growth rates                            
Total Revenue Growth % ...             -21.5 -2.61 -0.696 6.38 -3.60    
Staff Cost Growth % ...             -21.3 -6.10 1.17 14.2 13.2    
EBITDA Growth % ...             12.7 14.4 14.5 83.2 -43.2    
EBIT Growth % ...             49.9 50.9 34.2 133 -51.2    
Pre-Tax Profit Growth % ...             -121 49.8 221 125 -54.0    
Net Profit Growth % ...             -124 -8.23 132 225 -54.3    
ratios                            
ROE % ...             1.12 1.02 2.33 7.19 3.17    
ROA % ...             0.153 0.153 0.385 1.24 0.567    
ROCE % ...             0.396 0.378 0.974 2.71 1.05    
Gross Margin %               1.90 1.89 1.92 2.21 1.91    
EBITDA Margin %               0.360 0.423 0.488 0.840 0.494    
EBIT Margin %               0.139 0.215 0.291 0.639 0.323    
Net Margin %               0.058 0.055 0.128 0.392 0.186    
Payout Ratio % ...             54.0 46.2 -9.04 -0.810 93.7    
Cost of Financing % ... ... ... ... ... ... ... ... ... ... ... ...    
Net Debt/EBITDA ... ... ... ... ... ... ... ... ... ... ... ...    
balance sheet Unit 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
balance sheet                            
Cash & Cash Equivalents CZK mil               17.3 23.2 84.2 78.3 32.9    
Receivables CZK mil               1,942 1,561 1,336 2,220 1,915    
Inventories CZK mil               1,288 1,199 1,131 1,130 1,195    
Other ST Assets CZK mil               554 629 685 71.1 72.0    
Current Assets CZK mil               3,801 3,413 3,236 3,500 3,215    
Property, Plant & Equipment CZK mil               191 174 180 171 192    
LT Investments & Receivables CZK mil ... ... ... ... ... ... ... ... ... ... ... ...    
Intangible Assets CZK mil               16.0 22.1 21.1 16.8 11.2    
Goodwill CZK mil               0 0 0 0 0    
Non-Current Assets CZK mil               219 208 218 203 219    
Total Assets CZK mil               4,043 3,626 3,459 3,713 3,440    
                               
Trade Payables CZK mil               1,806 1,497 1,353 1,609 1,408    
Short-Term Debt CZK mil               1,530 1,422 1,417 1,445 1,385    
Other ST Liabilities CZK mil               126 126 89.0 19.7 6.44    
Current Liabilities CZK mil               3,462 3,046 2,859 3,074 2,800    
Long-Term Debt CZK mil ...             0 0 0 0 0    
Other LT Liabilities CZK mil ...             4.96 1.73 5.98 0 0    
Non-Current Liabilities CZK mil               4.96 1.73 5.98 0 0    
Liabilities CZK mil               3,467 3,047 2,865 3,074 2,800    
Equity Before Minority Interest CZK mil               576 579 594 639 640    
Minority Interest CZK mil               0 0 0 0 0    
Equity CZK mil               576 579 594 639 640    
growth rates                            
Total Asset Growth % ...             -6.50 -10.3 -4.63 7.36 -7.37    
Shareholders' Equity Growth % ...             0.515 0.550 2.57 7.52 0.199    
Net Debt Growth % ... ... ... ... ... ... ... ... ... ... ... ... ...  
Total Debt Growth % ... ...           -10.8 -7.05 -0.364 2.03 -4.17    
ratios                            
Total Debt CZK mil ...             1,530 1,422 1,417 1,445 1,385    
Net Debt CZK mil ... ... ... ... ... ... ... ... ... ... ... ...    
Working Capital CZK mil               1,424 1,263 1,114 1,741 1,702    
Capital Employed CZK mil               1,643 1,471 1,332 1,944 1,921    
Net Debt/Equity % ... ... ... ... ... ... ... ... ... ... ... ...    
Current Ratio               1.10 1.12 1.13 1.14 1.15    
Quick Ratio               0.566 0.520 0.497 0.748 0.696    
cash flow Unit 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
cash flow                            
Net Profit CZK mil               6.41 5.89 13.6 44.3 20.3    
Depreciation CZK mil               24.3 22.2 20.9 22.7 18.6    
Non-Cash Items CZK mil ...             -125 -63.0 -58.6 535 -10.0    
Change in Working Capital CZK mil ...             -52.8 161 149 -627 39.3    
Total Cash From Operations CZK mil               -147 126 125 -25.5 68.2    
                               
Capital Expenditures CZK mil               -23.9 -12.1 -27.5 -9.55 -33.3    
Other Investing Activities CZK mil               1.16 1.75 0.139 0.440 0.030    
Total Cash From Investing CZK mil               -22.7 -10.4 -27.4 -9.11 -33.3    
                               
Dividends Paid CZK mil ...             -3.46 -2.72 1.23 0.359 -19.0    
Issuance Of Debt CZK mil ... ...           -186 -108 -5.18 28.8 -60.2    
Total Cash From Financing CZK mil               -1.91 -110 -36.3 28.8 -20.1    
Net Change In Cash CZK mil               -172 5.88 61.0 -5.84 14.8    
ratios                            
Days Sales Outstanding days               64.5 53.2 45.9 71.7 64.1    
Days Sales Of Inventory days               43.6 41.7 39.6 37.3 40.8    
Days Payable Outstanding days               61.2 52.0 47.4 53.1 48.1    
Cash Conversion Cycle days               47.0 42.9 38.1 55.9 56.9    
Cash Earnings CZK mil               30.7 28.1 34.5 67.0 38.9    
Free Cash Flow CZK mil               -170 116 97.2 -34.6 34.9    
Capital Expenditures (As % of Sales) %               0.217 0.113 0.259 0.084 0.306    
other ratios Unit 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
                             
Employees               466 438 437 454 456    
Cost Per Employee USD per month               1,206 1,103 1,001 1,041 1,261    
Cost Per Employee (Local Currency) CZK per month               23,591 23,569 23,899 26,266 29,592    
Staff Cost (As % of Sales) %               1.20 1.16 1.18 1.27 1.49    
Effective Tax Rate %               -25.3 23.2 44.5 19.9 20.4    
Total Revenue Growth (5-year average) % ... ... ... ... ...     -1.77 -3.07 -5.52 -4.48 -4.89    
Total Revenue Growth (10-year average) % ... ... ... ... ... ... ... ... ... ... 0.928 -0.697    

Get all company financials in excel:

Download Sample   $19.99

PHARMOS's Cash & Cash Equivalents rose 39.7% yoy to CZK 51.9 mil in 2019

By Helgi Analytics - June 23, 2021

PHARMOS's total assets reached CZK 3,460 mil at the end of 2019, down 0.661% compared to the previous year. Current assets amounted to CZK 3,099 mil, or 89.6% of total assets while cash stood at CZK 51.9 mil at the end of 2019. ...

PHARMOS's Total Cash From Operations fell 95.7% yoy to CZK 7.52 mil in 2019

By Helgi Analytics - June 23, 2021

PHARMOS's operating cash flow stood at CZK 7.52 mil in 2019, down 95.7% when compared to the previous year. Historically, between 2006 - 2019, the firm’s operating cash flow reached a high of CZK 177 mil in 2018 and a low of CZK -147 mil in 2013. ...

PHARMOS's ROCE rose 118% yoy to 0.527% in 2019

By Helgi Analytics - June 23, 2021

PHARMOS made a net profit of CZK 11.2 mil in 2019, up 128% compared to the previous year. Historically, between 2006 and 2019, the company's net profit reached a high of CZK 44.3 mil in 2016 and a low of CZK -27.0 mil in 2012. The result implies a return ...

PHARMOS's Net Debt/EBITDA fell 20.6% yoy to 21.7 in 2019

By Helgi Analytics - June 23, 2021

PHARMOS's net debt stood at CZK 1,245 mil and accounted for 191% of equity at the end of 2019. The ratio is down 10.3 pp compared to the previous year. Historically, the firm’s net debt to equity reached a high of 201% in 2018 and a low of 19...

PHARMOS's Capital Expenditures rose 94.6% yoy to CZK 13.0 mil in 2019

By Helgi Analytics - June 23, 2021

PHARMOS invested a total of CZK 13.0 mil in 2019, down 94.6% compared to the previous year. Historically, between 2006 - 2019, the company's investments stood at a high of CZK 241 mil in 2018 and a low of CZK 6.26 mil in 2011. As a pe...

More News

PHARMOS, a.s. is a Czech Republic-based distributor of medications and pharmaceuticals to public and hospital pharmacies in Czech Republic. The company was founded in 1991 and is based in Ostrava, Czech Republic. PHARMOS, a.s. operates as a subsidiary of Ceska Lekarnicka.

PHARMOS Logo

Finance

PHARMOS has been growing its sales by -0.691% a year on average in the last 5 years. EBITDA has grown on average by 4.91% a year during that time to total of CZK 57.5 mil in 2019, or 0.556% of sales. That’s compared to 0.569% average margin seen in last five years.

The company netted CZK 11.2 mil in 2019 implying ROE of 1.72% and ROCE of 0.527%. Again, the average figures were 3.03% and 1.10%, respectively when looking at the previous 5 years.

PHARMOS’s net debt amounted to CZK 1,245 mil at the end of 2019, or 191% of equity. When compared to EBITDA, net debt was 21.7x, down when compared to average of 24.5x seen in the last 5 years.